| 1. |
Balint B, Vincent A, Meinck HM, et al. Movement disorders with neuronal antibodies: syndromic approach, genetic parallels and patho-physiology. Brain, 2018, 141(1): 13-36.
|
| 2. |
Binks SNM, Klein CJ, Waters P, et al. LGI1, CASPR2 and related antibodies: a molecular evolution of the phenotypes. J Neurol Neurosurg Psychiatry, 2018, 89(5): 526-534.
|
| 3. |
陳卓, 崔詩爽, 劉曉英, 等. 富亮氨酸膠質瘤失活 1 蛋白抗體致面-臂肌張力障礙發作的病例一例及文獻回顧. 診斷學理論與實踐, 2019, 18(4): 473-474.
|
| 4. |
Irani SR, Buckley C, Vincent A, et al. Immunotherapy-responsive seizure-like episodes with potassium channel antibodies. Neurology, 2008, 71(20): 1647-1648.
|
| 5. |
Irani SR, Michell AW, Lang B, et al. Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol, 2011, 69(5): 892-900.
|
| 6. |
Iyer, RS, Ramakrishnan TCR, Shinto A, et al. Faciobrachial dystonic seizures result from fronto-temporo-basalganglial network involvement. Epilepsy Behav Case Rep, 2017, 8(1): 47-50.
|
| 7. |
Lai M, Huijbers MG, Lancaster E, et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan’s syndrome and acquired neuromyotonia. Brain, 2010, 133(9): 2734-2748.
|
| 8. |
Kotsenas AL, Watson RE, Pittock SJ, et al. MRI findings in autoimmune voltage-gated potassium channel complex encephalitis with seizures: one potential etiology for mesial temporal sclerosis. AJNR Am J Neuroradiol, 2014, 35(1): 84-88.
|
| 9. |
Striano P. Faciobrachial dystonic attacks: seizures or movement disorder? Ann Neurol, 2011, 70(1): 179-180.
|
| 10. |
Gadoth A, Zekeridou A, Klein CJ, et al. Elevated LGI1-IgG CSF index predicts worse neurological outcome. Ann Clin Transl Neurol, 2018, 5(5): 646-650.
|
| 11. |
Yang X, LiAN, ZhaoXH, et al. Clinical features of patients with anti-leucine-rich glioma inactivated-1 protein associated encephalitis: a Chinese case series. Int J Neurosci, 2019, 129(8): 754-761.
|
| 12. |
Thompson J, Bi M, Murchison AG, et al. The importance of early immunotherapy in patients with faciobrachial dystonic seizures. Brain, 2018, 141(2): 348-356.
|
